Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Alimentary Pharmacology & Therapeutics|December 27, 2025
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Authors' ReplyEric Lawitz, Linda Greenbaum
Expert Review of Gastroenterology & Hepatology|December 1, 2017
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis CHope Hubbard, Eric Lawitz
Hepatology (Baltimore, Md.)|May 1, 2025
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat contentManuel Romero-Gómez, Eric Lawitz
The New England Journal of Medicine|August 16, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Edward J Gane
Hepatology Communications|July 21, 2018
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetesNaim Alkhouri, Fred Poordad, Eric Lawitz
Current Opinion in Pharmacology|November 10, 2017
Novel treatments for chronic hepatitis C: closing the remaining gapsNaim Alkhouri, Eric Lawitz, Fred Poordad
Hepatology Communications|May 8, 2019
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH TreatmentNaim Alkhouri, Eric Lawitz, Mazen Noureddin
Clinics in Liver Disease|October 16, 2015
Next-Generation Regimens: The Future of Hepatitis C Virus TherapyJohn Vizuete, Hope Hubbard, Eric Lawitz
Hepatology (Baltimore, Md.)|September 26, 2020
Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver DiseasesNaim Alkhouri, G Kesava Reddy, Eric Lawitz
Clinical Liver Disease|May 2, 2019
Management of patients with hepatitis C virus resistance-associated variants to NS5A inhibitors: Where are we now?Jennifer T Wells, Carmen Landaverde, Julio Gutierrez, et al.
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Alimentary Pharmacology & Therapeutics|December 27, 2025
Editorial: Combination Therapies for MASH: A Step Forward or More Complexity? Authors' ReplyEric Lawitz, Linda Greenbaum
Expert Review of Gastroenterology & Hepatology|December 1, 2017
Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis CHope Hubbard, Eric Lawitz
Hepatology (Baltimore, Md.)|May 1, 2025
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat contentManuel Romero-Gómez, Eric Lawitz
The New England Journal of Medicine|August 16, 2013
Sofosbuvir for previously untreated chronic hepatitis C infectionEric Lawitz, Edward J Gane
Hepatology Communications|July 21, 2018
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetesNaim Alkhouri, Fred Poordad, Eric Lawitz
Current Opinion in Pharmacology|November 10, 2017
Novel treatments for chronic hepatitis C: closing the remaining gapsNaim Alkhouri, Eric Lawitz, Fred Poordad
Hepatology Communications|May 8, 2019
Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH TreatmentNaim Alkhouri, Eric Lawitz, Mazen Noureddin
Clinics in Liver Disease|October 16, 2015
Next-Generation Regimens: The Future of Hepatitis C Virus TherapyJohn Vizuete, Hope Hubbard, Eric Lawitz
Hepatology (Baltimore, Md.)|September 26, 2020
Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver DiseasesNaim Alkhouri, G Kesava Reddy, Eric Lawitz
Clinical Liver Disease|May 2, 2019
Management of patients with hepatitis C virus resistance-associated variants to NS5A inhibitors: Where are we now?Jennifer T Wells, Carmen Landaverde, Julio Gutierrez, et al.
Pageof 16